Nurix Therapeutics (NRIX) Net Margin (2019 - 2025)
Historic Net Margin for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to 576.13%.
- Nurix Therapeutics' Net Margin fell 1353800.0% to 576.13% in Q4 2025 from the same period last year, while for Nov 2025 it was 314.9%, marking a year-over-year increase of 399500.0%. This contributed to the annual value of 314.9% for FY2025, which is 399500.0% up from last year.
- According to the latest figures from Q4 2025, Nurix Therapeutics' Net Margin is 576.13%, which was down 1353800.0% from 1094.77% recorded in Q3 2025.
- In the past 5 years, Nurix Therapeutics' Net Margin registered a high of 79.14% during Q2 2023, and its lowest value of 1094.77% during Q3 2025.
- Its 5-year average for Net Margin is 399.97%, with a median of 380.48% in 2021.
- Its Net Margin has fluctuated over the past 5 years, first skyrocketed by 4119600bps in 2023, then plummeted by -7058600bps in 2025.
- Nurix Therapeutics' Net Margin (Quarter) stood at 509.59% in 2021, then crashed by -35bps to 688.74% in 2022, then soared by 60bps to 276.77% in 2023, then plummeted by -59bps to 440.75% in 2024, then tumbled by -31bps to 576.13% in 2025.
- Its Net Margin was 576.13% in Q4 2025, compared to 1094.77% in Q3 2025 and 98.66% in Q2 2025.